Sabesp Delivers 92,000 Smart Water Meters Powered by the Sigfox 0G Network Operated by WND in Brazil
19.5.2021 10:35:00 EEST | Business Wire | Press release
Sabesp, one of the largest water and sewage service providers in the world, today announces that it has successfully completed the implementation of 100,000 smart water meters with Internet of Things (IoT) technology. The project, which is one of the largest in Latin America, introduces water consumption telemeasurement in Sabesp's 100,000 largest consumers in the Metropolitan Region of São Paulo.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210519005356/en/
Sabesp smart water meters (Photo: Sigfox)
The Metrolink consortium is delivering the project and comprises of companies Laager and Vita Ambiental, which won the contract after a competitive bidding process Sabesp started at the end of 2018.
WND's Sigfox 0G network was the communication technology selected by Sabesp for more than 92,000 of the total connected water meters. WND is the exclusive operator of Sigfox technology in Brazil. Sigfox technology enables the transport of data wirelessly, at low cost, over long distances, with minimum energy consumption. The devices will be in operation for at least five years without changing or recharging the battery.
Telemetering – the remote reading of meters – automates the process of measuring water consumption. The task was performed manually once a month and can now be performed multiple times a day. In addition to measurement, the system also generates alarms and important statistics about the operation of the entire water network. All of these new features bring reliability, transparency and savings to consumers and unprecedented operational efficiency for Sabesp.
Ricardo Batista, Sabesp's Division Manager and responsible for the project, comments: "The project marked the large-scale adoption of the IoT concept by Sabesp. The new technology enables our customers to monitor water consumption daily, as well as leak detection, saving money and preserving the environment, in addition to better management of resources by our company. We hope to be able to expand the project in the coming years."
According to Felipe Duque Estrada, CEO of Laager, the success of the project is largely due to the partnership with Sigfox and WND Brazil: "The adoption of 0G network technologies from Sigfox ensured the economic and technological viability of the project."
José Almeida, Deputy CEO of WND Brazil, adds: "Thanks to Sabesp's pioneering approach, Laager's expertise and our work together, we have delivered one of the largest IoT projects in the Americas. The results achieved demonstrate, without any doubt, that our technology and business model are the best choices for IoT projects today."
Carlos Beato, VP Americas at Sigfox concludes: “We are incredibly proud of SABESP’s achievement and visionary take on smart water metering. The benefits of such a solution go far beyond remote reading. It truly transforms the customer experience and Quality of Service.”
*****
Sabesp – Companhia de Saneamento Básico do Estado de São Paulo (http://www.sabesp.com.br/) is the largest sanitation company in the Americas and the fourth largest in the world in the population served. It is responsible for the supply of water, sewage collection and treatment in 375 municipalities in the State of São Paulo, besides representing 30% of the investment in basic sanitation made in Brazil.
Laager Tecnologias Sustentáveis Ltda is a company specialized in technological solutions aimed at sustainability. Its devices make it possible to control the consumption of water, gas and electricity, besides allowing greater efficiency in consumption. The company has an advanced system of individualization of these resources, which can be applied to small, medium and large consumers.
Vita Ambiental is a traditional specialized Engineering Services provider for sanitation companies, focusing on reducing losses and operational optimizations.
WND Brazil, which is part of the WND Group (https://www.wndgroup.io/), operates in the IoT (Internet of Things) market through the implementation of a national public network, in a B2B (Business to Business) model that allows the sale of connectivity at low cost. In just three years of operation in Brazilian territory, the company is already present in all capital cities of the country, covering an area with a population of more than 120 million inhabitants and serving more than 360 cities. WND Brazil is a pioneer in a national public network dedicated exclusively to IoT using Sigfox technology.
Sigfox is the 0G network pioneer and the world’s leading IoT (Internet of Things) service provider. Sigfox offers a unique combination of ultra-low cost and ultra-low power technologies supported by a global network, enabling businesses to gain visibility and track their assets worldwide. With more than 17 million connected devices and 70 million messages sent a day, Sigfox helps its customers to extract crucial data at the lowest cost and to accelerate their digital transformation in key areas such as Asset Tracking and Supply Chain.
ISO 9001 certified and surrounded by a large ecosystem of partners and IoT key players, Sigfox was founded in 2010 and is headquartered in Labège, France, with offices in Boston, Dallas, Dubai, Madrid, Paris, Sao Paulo, Singapore and Tokyo.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210519005356/en/
Contact information
Sigfox
Antoine Mège, PR & Content Manager
antoine.mege@sigfox.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
